Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALBALON vs ADVIL CONGESTION RELIEF
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Naphazoline is an imidazoline derivative that acts as a direct-acting sympathomimetic amine, stimulating alpha-adrenergic receptors in the conjunctival arterioles, resulting in vasoconstriction and decreased congestion.
ibuprofen: non-selective COX-1/COX-2 inhibitor reducing prostaglandin synthesis; phenylephrine: alpha-1 adrenergic receptor agonist causing vasoconstriction
FDA-approved: Relief of redness and itching of the eye due to minor eye irritations (e.g., smoke, dust, wind, swimming, or wearing contact lenses).,Off-label: Treatment of allergic conjunctivitis symptoms (as an adjunct).
temporary relief of nasal congestion,sinus pressure,headache,fever,minor aches and pains associated with common cold or flu
1-2 drops in affected eye(s) every 3-4 hours; frequency may be increased to every 2 hours in severe cases.
1 tablet (ibuprofen 200 mg / phenylephrine 10 mg) orally every 4 hours while symptoms persist, not to exceed 6 tablets in 24 hours.
Terminal elimination half-life is 4-6 hours; clinically, dosing every 6-8 hours is recommended, with adjustments in renal impairment
Ibuprofen: 2-4 hours (short half-life requires frequent dosing). Pseudoephedrine: 5-8 hours (longer in alkaline urine). Context: Half-life prolonged in renal impairment.
Primarily metabolized in the liver via oxidative deamination by monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT).
ibuprofen: primarily hepatic via CYP2C9; phenylephrine: primarily hepatic via monoamine oxidase (MAO) and sulfation
Primarily renal excretion of unchanged drug (approximately 70-80%) with minor biliary/fecal elimination (10-15%)
Renal: ~90% as unchanged drug and metabolites (ibuprofen: <10% unchanged, pseudoephedrine: 43-96% unchanged). Biliary/fecal: minimal (<5%).
Approximately 99% bound to serum albumin and alpha-1-acid glycoprotein
Ibuprofen: >99% bound to albumin. Pseudoephedrine: 20-30% bound to albumin.
0.5-0.8 L/kg, indicating distribution into total body water with moderate tissue binding
Ibuprofen: 0.1-0.2 L/kg (low, reflects high protein binding). Pseudoephedrine: 2.6-3.5 L/kg (extensive tissue distribution).
Oral: 60-70% due to first-pass metabolism; Ophthalmic: negligible systemic absorption (<1%)
Oral: Ibuprofen ~80-100% (high), Pseudoephedrine ~100% (high).
No dosage adjustment required; systemic absorption minimal.
Avoid use if Cr Cl <30 m L/min. For Cr Cl 30-59 m L/min, use lowest effective dose and shortest duration.
No dosage adjustment required; not studied in hepatic impairment.
Avoid use in severe hepatic impairment (Child-Pugh class C). For moderate impairment (Child-Pugh class B), use with caution and at the lowest effective dose.
Children ≥3 years: same as adult dosing; children <3 years: safety and efficacy not established.
Not recommended in children under 12 years of age due to phenylephrine component. For children 12 years and older, same as adult dosing.
No specific adjustment; use with caution due to possible increased sensitivity to anticholinergic effects.
Start at the low end of dosing range; avoid use in patients 65 years and older if possible due to increased risk of adverse effects; if necessary, use lowest effective dose for shortest duration.
No FDA black box warning.
ibuprofen carries a black box warning for increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal, and for serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines
Use with caution in patients with cardiovascular disease (e.g., hypertension, arrhythmias) or hyperthyroidism due to systemic absorption.,Prolonged use may lead to rebound congestion (rhinitis medicamentosa) if used intranasally; ocular overuse may cause reactive hyperemia.,Avoid in patients with narrow-angle glaucoma (risk of angle closure).,Monitor for systemic effects (e.g., dizziness, headache, palpitations).
cardiovascular risk,gastrointestinal risk,renal effects,avoid concomitant use of other NSAIDs,hypertension,hyperthyroidism,diabetes,heart disease,use with MAOIs may cause hypertensive crisis
Hypersensitivity to naphazoline or any component of the formulation.,Narrow-angle glaucoma (absolute contraindication).,Patients with severe cardiovascular disease (e.g., uncontrolled hypertension, coronary insufficiency).,Concomitant use with MAO inhibitors or within 14 days of MAO inhibitor therapy (risk of hypertensive crisis).
hypersensitivity to ibuprofen, phenylephrine, or any component,history of asthma, urticaria, or allergic-type reactions to aspirin or other NSAIDs,perioperative pain in setting of coronary artery bypass graft (CABG) surgery,severe hypertension,severe coronary artery disease,use of MAOIs or within 14 days of stopping MAOIs
No specific food interactions; however, avoid alcohol as it may exacerbate ocular irritation or dizziness.
Avoid alcohol consumption due to increased risk of GI bleeding and liver damage. No specific food interactions; take with food or milk to reduce stomach upset. Caffeine may exacerbate pseudoephedrine's stimulant effects; limit caffeine intake.
AUX: Category C. Naphazoline is an imidazoline sympathomimetic with potential for vasoconstriction; systemic absorption may reduce uterine blood flow. First trimester: limited human data; animal studies not evaluated for malformations. Second/third trimester: possible fetal hypoxia due to vasoconstriction; avoid use near term due to risk of neonatal tachycardia, hypertension, and irritability.
First trimester: Avoid due to potential increased risk of cardiac defects and gastroschisis from NSAIDs. Second trimester: Use with caution; ibuprofen may cause oligohydramnios and premature ductus arteriosus constriction. Third trimester: Contraindicated due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment. Phenylephrine: Limited human data; animal studies show fetal abnormalities at high doses; avoid in first trimester due to potential vascular disruption.
No human data on excretion in breast milk. M/P ratio unknown. Naphazoline likely passes into milk due to low molecular weight; risk of infant vasoconstrictive effects if absorbed. Use with caution; avoid prolonged or high-dose use while breastfeeding.
Ibuprofen: Excreted into breast milk in low amounts (M/P ratio ~0.07). Compatible with breastfeeding; minimal infant exposure. Phenylephrine: Not known if excreted in breast milk; M/P ratio unknown. Avoid due to potential for infant hypertension and irritability. Alternative decongestants preferred.
No dose adjustment recommended for topical ophthalmic use. Systemic absorption is negligible; however, if systemic effects occur, reduce frequency. Pregnancy may alter ocular pharmacokinetics, but no specific adjustment data available.
Pharmacokinetic changes in pregnancy: Increased volume of distribution and clearance for ibuprofen may require higher doses, but avoid due to fetal risks. No standard dose adjustment recommended; use lowest effective dose for shortest duration. Phenylephrine: No specific dosing adjustments in pregnancy; avoid use due to limited safety data.
ALBALON (naphazoline/pheniramine) ophthalmic solution: Use with caution in patients with cardiovascular disease or hypertension due to naphazoline's alpha-adrenergic effects; limit use to 3-4 days to avoid rebound conjunctival hyperemia; do not use in patients with narrow-angle glaucoma; remove contact lenses before instillation and wait 15 minutes before reinserting.
Advil Congestion Relief combines ibuprofen (NSAID) and pseudoephedrine (decongestant). Ibuprofen can cause nephrotoxicity; pseudoephedrine can elevate blood pressure and heart rate. Avoid in patients with uncontrolled hypertension, severe CAD, or MAOI use within 14 days. Use with caution in elderly due to increased risk of GI bleeding and CNS effects. Not recommended for children under 12 years.
Do not use while wearing soft contact lenses; remove lenses before using and wait at least 15 minutes before reinserting.,Avoid touching the dropper tip to any surface to prevent contamination.,Do not use more than 4 times daily or for longer than 72 hours without consulting a doctor; overuse can cause worsening redness.,Temporary stinging or blurred vision may occur upon instillation; do not drive until vision clears.,Seek medical attention if eye pain, vision changes, or persistent redness occur.
Do not take more than directed; do not use with other products containing ibuprofen or other NSAIDs (e.g., naproxen, aspirin) due to increased risk of stomach bleeding.,Avoid alcohol while taking this medication to reduce the risk of stomach irritation and bleeding.,Pseudoephedrine may cause insomnia, nervousness, or dizziness; take the last dose at least 4-6 hours before bedtime.,Stop use and consult a doctor if symptoms persist after 5 days (fever >3 days), if new symptoms appear, or if you experience signs of stomach bleeding (black/bloody stools, vomit with blood/coffee-grounds).,Do not use if you have heart disease, high blood pressure, thyroid disease, diabetes, glaucoma, or difficulty urinating due to an enlarged prostate unless directed by a doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALBALON vs ADVIL CONGESTION RELIEF, answered by our medical review team.
ALBALON is a Ophthalmic Antihistamine/Decongestant that works by Naphazoline is an imidazoline derivative that acts as a direct-acting sympathomimetic amine, stimulating alpha-adrenergic receptors in the conjunctival arterioles, resulting in vasoconstriction and decreased congestion.. ADVIL CONGESTION RELIEF is a NSAID/Decongestant Combination that works by ibuprofen: non-selective COX-1/COX-2 inhibitor reducing prostaglandin synthesis; phenylephrine: alpha-1 adrenergic receptor agonist causing vasoconstriction. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALBALON and ADVIL CONGESTION RELIEF depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALBALON is: 1-2 drops in affected eye(s) every 3-4 hours; frequency may be increased to every 2 hours in severe cases.. The standard adult dose of ADVIL CONGESTION RELIEF is: 1 tablet (ibuprofen 200 mg / phenylephrine 10 mg) orally every 4 hours while symptoms persist, not to exceed 6 tablets in 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALBALON and ADVIL CONGESTION RELIEF in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALBALON is classified as Category C. AUX: Category C. Naphazoline is an imidazoline sympathomimetic with potential for vasoconstriction; systemic absorption may reduce uterine blood flow. First trimester: limited huma. ADVIL CONGESTION RELIEF is classified as Category C. First trimester: Avoid due to potential increased risk of cardiac defects and gastroschisis from NSAIDs. Second trimester: Use with caution; ibuprofen may cause oligohydramnios and. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.